Adagene Inks Third Cancer Trial Collaboration With Merck

Adagene Inc ADAG has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc MRK.
The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck's Keytruda (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies.
ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb developed to treat advanced solid tumors and non-Hodgkin's lymphoma.
Related: Adagene To Test Its Anti-CTLA-4 Antibodies In Combination With Keytruda In Solid Tumors.
Price Action: ADAG shares closed 4.02% lower at $17.80 on Wednesday.